# Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer

> **NCT01787006** · PHASE2 · COMPLETED · sponsor: **University Hospital Schleswig-Holstein** · enrollment: 74 (actual)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Cisplatin, 5-FU
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT01787006
- **Lead sponsor:** University Hospital Schleswig-Holstein
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2018-09-06
- **Final completion:** 2018-09-06
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2020-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01787006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01787006, "Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01787006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*